{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.17","value":"-3.0"},{"groupId":"OG001","spread":"4.25","value":"0.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"68"}],"units":"Participants"}],"title":"Weeks 9 to 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.22","value":"-4.9"},{"groupId":"OG001","spread":"7.14","value":"-3.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"title":"Weeks 33 to 48"}],"denoms":[{"counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"68"}],"units":"Participants"}],"description":"Mean change in total number of Red Blood Cells (RBC) units transfused over a fixed 16-week period (Week 9-24 or Week 33-48) from the total number of RBC units transfused in the 16 weeks immediately on or prior to first dose of study treatment.","dispersionType":"Standard Deviation","groups":[{"description":"Luspatercept 1.0 mg/Kg SC on Day 1 of each 21-day treatment cycle","id":"OG000","title":"Luspatercept"},{"description":"Placebo (Volume equivalent to experimental arm) SC on Day 1 of each 21-day treatment cycle","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"All treated participants with available measurements at the indicated timepoints","reportingStatus":"POSTED","timeFrame":"At Baseline (16 weeks prior to first dose of study treatment) and Weeks 9 to 24 or Weeks 33 to 48","title":"Change From Baseline in RBC Units Transfused Over Fixed 16-Week Period","type":"SECONDARY","unitOfMeasure":"Units"}